drugset / Trial / NCT06589440
Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, dose escalation and expansion, multi-center phase 2 study evaluating the safety and efficacy of SR-8541A administered orally in combination with intravenous botensilimab and balstilimab in subjects with MSS-CRC with and without active liver metastases.
Timeline
- Start
- 2024-11-20
- Primary completion
- 2027-09
- Completion
- 2027-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Balstilimab | Monoclonal antibody | — | Oral |
| Subject | Balstilimab | Monoclonal antibody | — | Intravenous |
| Subject | Botensilimab | Monoclonal antibody | — | Intravenous |